AstraZeneca admits Covid-19 vaccine may cause blood clots in very rare cases – Pharmaceutical Technology

AstraZeneca has been embroiled in a class action lawsuit for its Covid-19 vaccine, admitting that the vaccine may cause incidences of thrombosis with thrombocytopenia syndrome (TTS).

As reported by The Telegraph on 28 April, the pharma giant wrote in a legal document submitted to the UK High Court in February, It is admitted that the AstraZeneca vaccine can, invery rarecases, cause TTS. The causal mechanism is not known. TTS is known to cause blood clots and low blood platelet counts.

A total of 51 cases have been filed in the High Court by victims and their families, with The Telegraph reporting that the plaintiffs are seeking compensation valued at approximately GBP 100m.

The vaccine, sold under brand names Covishield and Vaxzevria, has previously been linked to a risk of blood clots. In April 2021, the European Medicines Agencys (EMA) safety committee reported that a jab of the vaccine was associated with blood clots in the brain, abdomen, and arteries as well as thrombocytopenia. At the time, the EMA and the UK Medicines and Healthcare products Regulatory Agency (MHRA) declared that the benefits of the vaccine outweighed the potential risks and encouraged people to get vaccinated.

In a November 2021 press release, AstraZeneca reported that two billion doses of its vaccine were supplied to countries across the world less than 12 months after the first approval. The pharma giant also saw profits from its Covid-19 vaccine for the first time in 2022 and reported that it had delivered approximately 102 million doses of its vaccine through COVAX in Q4 2022.

AstraZenecas admission follows a year of legal battles for the lawsuit that alleges that the vaccine caused death and serious injury in multiple instances. According to The Telegraph, the first case was filed in 2023 when a patient reported that the vaccination left him with a permanent brain injury that developed from a blood clot and a bleed in the brain.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

As per a 29 April coroners report from the UK Courts and Tribunals Judiciary, the death of a 28-year-old patient is the latest case to associate blood clot side effects to AstraZenecas vaccine. The report concluded that the patient died from cerebral venous sinus thrombosis and Covid-19 vaccine-induced immune thrombotic thrombocytopenia.

This is not the first time in recent months that AstraZeneca has been embattled with lawsuits. In October 2023, the company paid $425m (352.37m) to settle lawsuits that claimed its heartburn medications, Nexium (esomeprazole) and Prilosec (omeprazole), caused chronic kidney disease.

Give your business an edge with our leading industry insights.

Continued here:

AstraZeneca admits Covid-19 vaccine may cause blood clots in very rare cases - Pharmaceutical Technology